DDInter1873 DDInter1960
Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.
Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail _Conus magus_ comprising 25 amino acids with three disulphide bonds.[A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be synthesized without loss of proper bond formation or structural elements.[A202829, A202832] Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.[A202829, A202835, A202838, A202841, A202850, A202859, L13389] Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt. To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.
Trimethobenzamide {u} (Compound) resembles {v} (Compound) Bevantolol
Trimethobenzamide {u} (Compound) resembles {v} (Compound) Cisapride
Trimethobenzamide {u} (Compound) upregulates {v} (Gene) HIST1H2BK
Trimethobenzamide {u} (Compound) is included by {v} (Pharmacologic Class) Emesis Suppression
Trimethobenzamide {u} (Compound) causes {v} (Side Effect) Disorientation
Trimethobenzamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Midazolam
Trimethobenzamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Trimethobenzamide {u} may lead to a major life threatening interaction when taken with {v} Dextropropoxyphene
Trimethobenzamide (Compound) resembles Bevantolol (Compound)
Trimethobenzamide (Compound) resembles Cisapride (Compound)
Trimethobenzamide (Compound) upregulates HIST1H2BK (Gene)
Trimethobenzamide (Compound) is included by Emesis Suppression (Pharmacologic Class)
Trimethobenzamide (Compound) causes Disorientation (Side Effect)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Midazolam
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Trimethobenzamide may lead to a major life threatening interaction when taken with Dextropropoxyphene